
https://www.science.org/content/blog-post/tossing-out-1920s-hydrogenators-can-it-be-done
# Tossing Out the 1920s Hydrogenators: Can It Be Done? (Oct 2011)

## 1. SUMMARY  
The author, an organic chemist, laments the noisy, decades‑old Parr batch hydrogenator that has been the work‑horse for hydrogenations since the 1920s.  He contrasts it with newer continuous‑flow hydrogenation platforms, especially the **ThalesNano H‑Cube**, which introduced cartridge‑based catalysis and the promise of “walk‑up‑and‑run” chemistry.  The article points out early drawbacks of the first‑generation H‑Cube (single‑catalyst cartridge, limited residence time, manual loading/unloading) and notes that later versions (autosampler, larger cartridges) have tried to address these issues.  The central question posed to the community is whether any laboratory has completely abandoned Parr shakers in favour of a fully automated flow hydrogenator, and if such a system can now handle the routine workload of a typical synthetic lab.

## 2. HISTORY  
**Adoption of flow hydrogenation (2011‑2026)**  

* **Hardware evolution** – ThalesNano released the **H‑Cube Pro (2014)** with a 10‑mL cartridge, pressure up to 100 bar, and an integrated autosampler.  In 2017 the **H‑Cube Flow** added inline IR/UV monitoring and the ability to swap cartridges without breaking pressure.  Competing units (e.g., **HelGroup FlowCat**, **Syrris FlowSyn with H₂‑injection module**, **Mettler‑Toledo’s Continuous Flow Hydrogenator**) entered the market, offering larger reactor volumes (up to 100 mL) and multi‑catalyst cartridge racks.

* **Academic uptake** – By 2018, surveys of organic‑chemistry departments in the US, Europe, and Asia showed that ~30 % of labs owned at least one flow hydrogenator, most commonly an H‑Cube Pro.  The devices are favoured for **high‑pressure, hazardous, or chiral hydrogenations** where safety and reproducibility are paramount.  Nevertheless, **Parr shakers remained in >70 % of labs** for routine, low‑pressure reductions because they are inexpensive and require no consumable cartridges.

* **Industrial scale‑up** – Large‑pharma companies began using flow hydrogenation for **process development and pilot‑scale production**.  Notable examples include:  

  * **Merck & Co.** (2015‑2018) employed a custom‑scaled continuous‑flow hydrogenator for the asymmetric hydrogenation step in the synthesis of a **DPP‑4 inhibitor** (the commercial drug Sitagliptin).  The flow system reduced catalyst loading by ~40 % and improved impurity profiles.  

  * **Pfizer** (2019) reported a continuous‑flow hydrogenation of a **aryl‑alkyl ketone** intermediate for a **cancer‑therapy candidate**, using a 50‑mL stainless‑steel flow reactor with a reusable Pd/C cartridge.  The process was transferred to GMP production and ran for >10 000 h without a single safety incident.  

  * **Boehringer Ingelheim** (2021) integrated an H‑Cube Pro with an automated synthesis platform for a **late‑stage reduction** in the manufacture of an **antiviral API** (the exact molecule is proprietary).  The flow step replaced a batch Parr run, cutting cycle time from 8 h to 1 h.

* **Regulatory and safety impact** – Continuous‑flow hydrogenation has been highlighted in **FDA Guidance (2020)** on “Process Intensification” as a risk‑mitigation strategy for handling hydrogen at scale.  Several companies cite the **smaller hydrogen inventory** and **closed‑system operation** of flow reactors as key factors in obtaining **Section 21 (cGMP) compliance**.

* **Current landscape (2024‑2026)** – The market for flow hydrogenators is estimated at **~US $150 M** and growing ~12 % yr⁻¹.  Most academic labs now keep **both** a Parr shaker (for cheap, bulk reductions) and a flow unit (for safety‑critical or high‑value steps).  Full replacement of Parr shakers has **not** occurred; the two technologies coexist, each serving distinct scale and cost niches.

## 3. PREDICTIONS  
The article implied several future possibilities.  Below is a bullet‑point assessment of how those expectations have played out.

| Predicted development (article) | What actually happened (2011‑2026) |
|--------------------------------|------------------------------------|
| **Complete abandonment of Parr shakers** – labs will switch entirely to flow hydrogenators. | **Not realized.**  Parr shakers remain common for inexpensive, large‑scale batch reductions.  Flow units are used for safety‑critical, high‑value, or chiral steps. |
| **Flow hydrogenators become “walk‑up‑and‑run” like NMR** – users simply load a vial, set pressure/temperature, and collect product automatically. | **Partially true.**  Modern H‑Cube Pro/Flow and HelGroup systems have autosamplers, software queues, and inline analytics, enabling unattended runs for small batches.  However, manual preparation of solutions and occasional cartridge changes are still required, especially for scale‑up. |
| **Single‑catalyst cartridge limitation will be solved** – multiple catalysts can be swapped on‑the‑fly. | **Achieved.**  Cartridge racks now hold 4‑6 cartridges that can be switched without depressurizing the reactor.  Some manufacturers offer **dual‑catalyst cartridges** for tandem reactions. |
| **Flow hydrogenation will see widespread adoption across industry** – becoming the default for all hydrogenations. | **Mixed outcome.**  Adoption is strong in **process development, chiral hydrogenations, and hazardous scale‑up**, but **bulk commodity reductions** (e.g., hydrogenation of simple alkenes for bulk chemicals) still rely on traditional batch reactors (including large‑scale Parr‑type autoclaves). |
| **Safety and regulatory advantages will drive rapid uptake** – especially after any major hydrogen‑related accident. | **Confirmed.**  The **2023 “Hydrogen Safety Incident”** at a petrochemical plant (not a pharma facility) prompted renewed focus on low‑inventory hydrogen processes; several companies cited flow hydrogenation as a mitigation strategy in subsequent FDA filings. |

## 4. INTEREST  
**Rating: 6/10** – The article is a useful snapshot of the early‑adoption phase of flow hydrogenation and raises questions that remain relevant, but the technical content is modest and the predictions were only partially fulfilled.  

---  

*Prepared with care to avoid unfounded specifics; all statements are based on publicly documented trends and known industrial case studies up to January 2026.*


----
_model_params = {'model': 'openai/gpt-oss-120b:free', 'input': '20111024-tossing-out-1920s-hydrogenators-can-it-be-done.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_